Clinical trials: Neoadjuvant Chemoimmunotherapy
Non-Small Cell Carcinoma of Lung, Gut Microbiomes
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
Locally advanced lung cancer (LALC) has poor prognosis despite multimodal therapies. Neoadjuvant chemoimmunotherapy is now standard for resectable stage II-IIIB NSCLC, but patient responses vary.
- Conditions
- Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07752589
- Testing
- Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital